The legal battle over who can make and distribute a weight loss ingredient is brewing, and an Edmond telehealth provider is joining the fight.

People are buying semaglutide and tirzepatide, the key ingredients in Ozempic and Zepbound, from unconventional sources. Doctors have safety concerns.

Trump’s latest tariff vow threatens to disrupt supplies of obesity drugs such as Mounjaro and Wegovy as pharma giants face ‘chaos’ ...

States that do provide coverage have tried to manage costs by putting prescribing limits on the GLP-1s. There’s also some ...

The number of Americans taking cutting-edge weight-loss drugs like Ozempic, Wegovy and Zepbound has skyrocketed in recent ...

Because of this, both drugs are expected to work in the same way for weight loss. They’re also expected to cause similar side effects, including low blood sugar and fatigue. However, the price ...

A groundbreaking study from the University of British Columbia has revealed a potentially disturbing side effect for those taking popular weight loss medications containing semaglutide, such as ...

But the company is worried about the unintended consequences of encouraging coverage of weight-loss drugs, including Eli Lilly's (LLY) Zepbound and Novo Nordisk's (NVO) Wegovy. The other GLP-1s ...

Telehealth services offer several weight loss ... drug. The cost of Wegovy can vary widely depending on insurance coverage and which pharmacy a person chooses. According to Optum Perks, a free ...

Losing weight can help treat the condition, called pseudotumor cerebri. Last year, her doctor recommended she start a popular weight-loss drug ... behind the high prices of drugs like Wegovy ...

US-based pharmaceutical giant Eli Lilly has launched its diabetes and weight-loss drug, Mounjaro ... Indian public at a slightly more affordable price. Previously, patients had to obtain them ...

Wegovy, for example, had a $328 monthly list price in Germany and $1,349 in the United States, according to a KFF analysis of weight-loss drug prices released in August 2023. In their statements ...